Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01779050
Title Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Trastuzumab

Docetaxel

Cyclophosphamide + Epirubicin

Paclitaxel

Cyclophosphamide + Epirubicin + Fluorouracil

Carboplatin + Docetaxel

Cyclophosphamide + Docetaxel

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST